Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes

Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial

(2020) Christopher K. Rayner et al.   DIABETES CARE

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

(2020) Daniel R. Quast et al.   DIABETES CARE

GLP ‐1 receptor agonists and the appropriate measurement of gastric emptying

(2020) Michael Horowitz et al.   DIABETES OBESITY & METABOLISM

Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution

(2020) Ryan Jalleh et al.   Nutrients

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

(2020) Michael A. Nauck et al.   Molecular Metabolism

β-Carotene in the human body: metabolic bioactivation pathways – from digestion to tissue distribution and excretion

(2019) Torsten Bohn et al.   PROCEEDINGS OF THE NUTRITION SOCIETY

GLP-1 and PYY3-36 reduce high-fat food preference additively after Roux-en-Y gastric bypass in diet-induced obese rats

(2019) Ulrich Dischinger et al.   Surgery for Obesity and Related Diseases

GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones and Regional Body Fat Stores in Adults with Obesity

(2019) Hoda Kadouh et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

(2019) Mirna Abd El Aziz et al.   DIABETES OBESITY & METABOLISM

MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?

(2019) Michael A Nauck et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?

(2018) Raffaella Gentilella et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons

(2018) Masahiro Kawatani et al.   PEPTIDES

The Food Environment, Preference, and Experience Modulate the Effects of Exendin-4 on Food Intake and Reward

(2017) Ricardo Mella et al.   Obesity

Liraglutide suppression of caloric intake competes with the intake-promoting effects of a palatable cafeteria diet, but does not impact food or macronutrient selection.

(2017) Kellie M. Hyde et al.   PHYSIOLOGY & BEHAVIOR

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial

(2016) Mark M. Smits et al.   DIABETES CARE

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

(2016) Michael Nauck et al.   DIABETES CARE

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

The GLP-1 agonist exendin-4 attenuates self-administration of sweetened fat on fixed and progressive ratio schedules of reinforcement in rats

(2016) Kimberly A. Bernosky-Smith et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors

(2016) Sunil Sirohi et al.   PHYSIOLOGY & BEHAVIOR

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

(2015) Juris J. Meier et al.   DIABETES CARE

Activation of the GLP-1 Receptors in the Nucleus of the Solitary Tract Reduces Food Reward Behavior and Targets the Mesolimbic System

(2015) Jennifer E. Richard et al.   PLoS One

Glucagon-Like Peptide-1 Receptor Agonists Increase Pancreatic Mass by Induction of Protein Synthesis

(2014) Jacqueline A. Koehler et al.   DIABETES

GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans

(2014) L. van Bloemendaal et al.   DIABETES

Risk of pancreatitis in patients treated with incretin-based therapies

(2014) Juris J. Meier et al.   DIABETOLOGIA

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

(2014) Anna Secher et al.   JOURNAL OF CLINICAL INVESTIGATION

Gastric emptying and glycaemia in health and diabetes mellitus

(2014) Liza K. Phillips et al.   Nature Reviews Endocrinology

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

(2013) C. Kapitza et al.   DIABETES OBESITY & METABOLISM

Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight

(2012) J. Jelsing et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes

(2011) Kana Inoue et al.   Cardiovascular Diabetology

The role of nausea in food intake and body weight suppression by peripheral GLP-1 receptor agonists, exendin-4 and liraglutide

(2011) Scott E. Kanoski et al.   NEUROPHARMACOLOGY

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET